bis(diazo)benzidine has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, Y; Ou, K; Shen, Q; Wang, Q; Zeng, C; Zhang, L | 1 |
| Guo, S; Jiang, B; Li, C; Li, X; Luo, J; Shi, D; Wang, L; Yu, R; Zheng, M | 1 |
2 other study(ies) available for bis(diazo)benzidine and Alloxan Diabetes
| Article | Year |
|---|---|
5-Bromo-3,4-dihydroxybenzaldehyde stabilizes diabetic retinal neurovascular units by inhibiting the inflammatory microenvironment.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Humans; Hyperglycemia; Interleukin-6; Mice; Retina; Tumor Necrosis Factor-alpha | 2023 |
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.
Topics: Animals; Benzidines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Hypoglycemic Agents; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2020 |